Trials / Completed
CompletedNCT03830463
Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers
A Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of CTP-692 in Fed and Fasted Conditions in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety and pharmacokinetic (PK) profile of single ascending doses of CTP-692 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-692 | Single oral dose |
| DRUG | Placebo | Single oral dose |
Timeline
- Start date
- 2019-01-24
- Primary completion
- 2019-03-28
- Completion
- 2019-03-28
- First posted
- 2019-02-05
- Last updated
- 2019-06-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03830463. Inclusion in this directory is not an endorsement.